STOCK TITAN

Zymeworks Announces $200 Million Share Repurchase Authorization

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
buybacks

Zymeworks (Nasdaq: ZYME) authorized a second 2026 share repurchase program allowing purchases of up to $200.0 million of common stock. The company intends to begin before the end of 2026 and expects to spend approximately $140.0 million through 2028.

Funding will come from its existing balance sheet and expected cash flows: $55 million in upfront fees from the Roche collaboration closing, expected before year-end 2026 pending HSR clearance, and a potential $100 million TRELEGY ELLIPTA milestone payment expected in the first quarter of 2027, subject to the applicable 2026 sales threshold. Zymeworks completed its initial 2026 repurchase program, which authorized up to $125.0 million. Approximately 68.7 million common shares were outstanding as of November 11, 2026.

Loading...
Loading translation...
5 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Up to $200.0 million authorized for repurchases through 2028; approximately $140.0 million expected, starting before year-end 2026. 11% of market cap
  • Moderate point. Forward-looking: it has not happened yet and may not happen.$55 million in upfront fees expected from Roche collaboration closing before year-end 2026 would help fund repurchases. 3% of market cap
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Potential $100 million TRELEGY ELLIPTA milestone payment expected in the first quarter of 2027 would help fund repurchases. 5.4% of market cap
  • Minor pointInitial 2026 repurchase program completed, following authorization to repurchase up to $125.0 million.
  • Minor point. Forward-looking: it has not happened yet and may not happen.2027 capital allocation plans include pipeline development and selective acquisitions alongside opportunistic repurchases.

Negative

  • Minor pointRoche collaboration closing remains pending HSR clearance, a condition for the expected upfront funding.
  • Minor point. Forward-looking: it has not happened yet and may not happen.TRELEGY ELLIPTA milestone payment depends on achievement of the applicable 2026 sales threshold.

News Explained

The Zymeworks $200.0 million ceiling is authorized, not a commitment: the company says it has no obligation to buy shares and may suspend or discontinue the program, so any reduction in outstanding shares depends on purchases actually made.

Key Figures

Repurchase authorization: Up to $200.0 million Expected repurchases: Approximately $140.0 million Roche upfront fees: $55 million +1 more
Repurchase authorization
Up to $200.0 million
Second 2026 program; repurchases may continue through 2028
Expected repurchases
Approximately $140.0 million
Company currently expects this spending through 2028
Roche upfront fees
$55 million
Expected before the end of 2026; pending HSR clearance
TRELEGY ELLIPTA milestone
Potential $100 million
Expected in the first quarter of 2027, subject to achievement of the applicable 2026 sales threshold

Previous Buybacks Reports

1 past event · Latest: May 14
Same Type 1 event
  1. May 14

    Share repurchase

    24h Move
    -0.1%

    Authorized up to $125 million in 2026 repurchases after ending the 2025 program

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

total shareholder return (tsr), hsr clearance, rule 10b5-1, rule 10b-18
4 terms
total shareholder return (tsr) financial
"expected contribution to Total Shareholder Return (TSR)"
Total shareholder return (TSR) measures how much an investment in a company's stock has grown over a specific period by combining the change in the share price and all dividends paid, expressed as a percentage. Think of it like tracking the total balance of a savings jar that increases both from added cash (dividends) and a rising sticker price on the jar (share price); investors use TSR to compare how well different stocks or managers deliver real, money-in-hand returns.
hsr clearance regulatory
"pending HSR clearance"
hsr clearance is approval under the U.S. Hart-Scott-Rodino (HSR) antitrust pre‑merger notification process that allows parties to close a transaction after the required federal waiting period has ended or the agencies have expressly cleared the deal. Companies above statutory size thresholds must file HSR notifications with the Federal Trade Commission and Department of Justice and then either wait the initial statutory waiting period or respond to an agency request for additional information (a “second request”), which extends review; clearance occurs when the waiting period expires without further action or when the agencies notify the parties they will not challenge the transaction. The practical effect is that HSR clearance removes the HSR-related legal bar to consummating the acquisition or merger, though separate antitrust litigation or other regulatory approvals may still be required.
rule 10b5-1 regulatory
"in accordance with Rule 10b5-1 of the Securities Exchange Act"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
rule 10b-18 regulatory
"and Rule 10b-18 of the Exchange Act"
Rule 10b-18 is a regulation that sets strict rules for how a company's executives and employees can buy back their own company's stock from the market. It helps ensure that these buybacks happen in a fair and transparent way, reducing the chance of market manipulation. This is important for investors because it offers protection against unfair practices and promotes confidence in the integrity of the stock market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
  • Zymeworks intends to commence the Share Repurchase Program with $140.0 million in share repurchases expected through 2028, with flexibility to adjust the pace of repurchases based on market opportunities, cash flow, and expected contribution to Total Shareholder Return (TSR)
  • Zymeworks intends to balance capital allocation for 2027 thoughtfully across disciplined R&D pipeline development, selective M&A transactions and opportunistic share repurchases to grow underlying enterprise value while returning capital to shareholders through reducing share count over time

VANCOUVER, British Columbia, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that its Board of Directors has authorized a second 2026 share repurchase program under which the Company may repurchase up to $200.0 million of its outstanding common stock, par value $0.00001 per share.

Zymeworks completed its initial 2026 share repurchase program under which the Company was authorized to repurchase up to $125.0 million of its outstanding common stock. As of November 11, 2026, the Company had approximately 68.7 million outstanding common shares.

Zymeworks intends to commence the second 2026 Share Repurchase Program before the end of 2026, which authorizes up to $200.0 million in repurchases through 2028, demonstrating the Company’s continued commitment to returning capital to stockholders. The Company currently expects to spend approximately $140.0 million through 2028 under the program, while retaining the ability to adjust the pace of repurchases as it sees fit. The authorization provides flexibility to adapt to market conditions and opportunities to reduce share count with attractive potential contributions to long-term TSR.

“As we look ahead, our focus remains on allocating capital thoughtfully to support long-term growth and shareholder value,” said Kristin Stafford, CPA, Chief Financial Officer of Zymeworks. “Our priorities include disciplined pipeline development, selective M&A and opportunistic share repurchases, with $140.0 million in repurchases expected through 2028. Maintaining flexibility around the pace of repurchases allows us to respond to market conditions and cash flow while prioritizing opportunities to create lasting value for shareholders.”

The Share Repurchase Program will be funded through the Company’s existing balance sheet, and expected near-term cash flows of $55 million in upfront fees from the closing of the Roche collaboration expected before the end of 2026, pending HSR clearance, and the potential $100 million TRELEGY ELLIPTA® milestone payment expected in the first quarter of 2027, subject to achievement of the applicable 2026 sales threshold. The shares may be repurchased from time to time in open market transactions, or other means in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Rule 10b-18 of the Exchange Act. The timing, number of shares repurchased, and prices paid for the shares under this program will depend on general business and market conditions as well as corporate and regulatory limitations, prevailing stock prices, and other considerations. The second 2026 share repurchase program may be suspended or discontinued at any time and does not obligate the Company to acquire any amount of common stock.

About Zymeworks Inc.

Zymeworks is a global biotechnology company building a diversified portfolio of healthcare assets designed to generate durable cash flows while advancing innovative medicines for difficult-to-treat diseases. The Company’s asset and royalty aggregation strategy combines a growing portfolio of commercial and near-commercial assets, including YUPELRI® (revefenacin), with a differentiated internal research and development engine. Zymeworks’ portfolio also includes Ziihera® (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by Zymeworks and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines, and pasritamig, a clinical-stage multispecific antibody developed by Johnson & Johnson using Zymeworks’ proprietary antibody engineering technologies.

Zymeworks is advancing a diverse pipeline of novel biotherapeutics, leveraging its proprietary Azymetric™ platform and expertise in antibody-drug conjugates, multispecific antibodies and other next-generation antibody technologies. These capabilities, together with Zymeworks’ integrated drug development expertise, enable the Company to develop differentiated therapeutics and create value through both internal innovation and strategic partnerships.

For more information about Zymeworks, its portfolio and pipeline, visit www.zymeworks.com and follow @ZymeworksInc on X.

Cautionary Note Regarding Forward-Looking Statements

This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to Zymeworks’ ability to execute the share repurchase program, in whole or in part; HSR clearance and the closing of the agreement with Roche; achievement of the applicable 2026 sales threshold for TRELEGY ELLIPTA®; Zymeworks’ flexibility to invest in its R&D pipeline and pursue strategic opportunities while returning capital to stockholders; expected benefits to stockholders of share repurchases; Zymeworks’ expectations regarding implementation of its long-term strategy to maximize value creation; Zymeworks’ and its partners’ clinical development of product candidates; potential safety profile and therapeutic effects of product candidates; the commercial potential of technology platforms and product candidates; the anticipated benefits of its collaboration agreements; and other information that is not historical information. When used herein, words such as “plan”, “believe”, “expect”, “may”, “continue”, “anticipate”, “potential”, “will”, “on track”, “progress”, “preserve”, “intend”, “could”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; Zymeworks may not be able to successfully execute the share repurchase program; the anticipated benefits of the share repurchase program may not be realized; Zymeworks may not achieve milestones or receive additional payments or royalties under its collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions, including the impact of tariffs; potential negative impacts of FDA regulatory delays and uncertainty around recent policy developments, changes in the leadership of federal agencies such as the FDA, staff layoffs, budget cuts to agency programs and research, and changes in drug pricing controls; the impact of pandemics and other health crises on Zymeworks’ business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks’ behalf; zanidatamab may not be successfully commercialized; Zymeworks’ business strategy related to anticipated and potential future milestones and royalty streams and existing and potential new partnerships may not be successfully implemented; Zymeworks’ evolution of its business strategy may not deliver meaningful stockholder returns; Zymeworks may be unsuccessful in actively managing and/or aggregating revenue-generating assets alongside its active R&D operations; ongoing and future clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; data providing early validation of our antibody drug conjugate platform and next generation pipeline programs may not be replicated in future studies; Zymeworks’ assumptions and estimates regarding its financial condition, future financial performance and estimated cash runway may be incorrect; inability to maintain or enter into new partnerships or strategic collaborations; the inability of Zymeworks to identify and consummate a strategic acquisition; and the factors described under “Risk Factors” in Zymeworks’ quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedarplus.ca).

Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.

Contacts:

Investor Inquiries:
Shrinal Inamdar
Vice President, Investor Relations
(604) 678-1388
ir@zymeworks.com   

Media Inquiries:
Diana Papove
Vice President, Corporate Communications
(604) 678-1388
media@zymeworks.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much stock does Zymeworks plan to repurchase under its second 2026 program?

Zymeworks authorized repurchases of up to $200.0 million through 2028 and currently expects to spend approximately $140.0 million. The company intends to begin the program before the end of 2026.

How will Zymeworks carry out purchases under its second 2026 share repurchase program?

Shares may be purchased through open market transactions or other means in accordance with Rule 10b5-1 and Rule 10b-18. Timing, purchase prices and share quantities will depend on business and market conditions, corporate and regulatory limitations, prevailing stock prices and other considerations. The authorization does not require any purchases.

Keep reading